When you pick up a prescription at the pharmacy, you might not think about whether the pill in your hand is the exact same as the one your doctor prescribed. But behind the scenes, a strict system is in place to make sure it is. This system is called therapeutic equivalence codes, and it’s how the U.S. Food and Drug Administration (FDA) decides which generic drugs can be swapped in for brand-name medications without changing how well they work or how safe they are.
It’s not enough for a generic drug to have the same active ingredient. It has to perform the same way in your body. That’s where the Orange Book comes in. Officially named Approved Drug Products with Therapeutic Equivalence Evaluations, this public database has been the FDA’s go-to reference since 1980. Every generic drug that’s been approved gets a code-usually one or two letters-that tells pharmacists and doctors whether it’s safe to substitute.
What Do the Letters Mean?
The code starts with a single letter: A or B. If it’s an A, the drug is considered therapeutically equivalent to the brand-name version. That means it can be swapped without any concerns. If it’s a B, the FDA says more information is needed. It doesn’t mean the drug is unsafe-it just means the evidence isn’t clear enough yet to guarantee it works exactly the same.
But the A rating has more detail. For example:
- AB means the drug has passed bioequivalence testing. This is the most common rating. Most simple pills-like antibiotics or blood pressure meds-fall into this category.
- AB1, AB2, AB3, AB4 are used when there’s more than one brand-name drug as a reference. If your doctor prescribes one brand, but the pharmacy has a generic that matches a different brand, these numbers help match the right one.
Now, the B codes are trickier. They tell you why the drug hasn’t been cleared for automatic substitution:
- BC = Extended-release tablets or capsules where the release pattern might differ.
- BD = Known bioequivalence problems in the past.
- BE = Delayed-release products like enteric-coated pills.
- BT = Topical creams or ointments where absorption is hard to measure.
- BN = Inhalers or nebulizer products.
- BX = Not enough data to make a call.
These aren’t random labels. Each one comes from real data. For example, a cream that treats eczema might have the same ingredients as the brand, but if the base (the non-active part) is different, it might not absorb the same way into the skin. That’s why it gets a BT code.
Why This Matters in Real Life
Imagine a pharmacist filling a prescription for a generic version of a cholesterol drug. The label says “Atorvastatin 20 mg.” The pharmacist checks the Orange Book and sees the code is AB. That means they can legally substitute it without asking the doctor. In 49 U.S. states, that’s allowed by law.
But if the code is BC, the pharmacist can’t just swap it. They might call the doctor. Or they might check if the patient has had problems with other extended-release versions before. In 38 states, pharmacists are required to notify the prescriber if they’re substituting a B-rated drug.
According to a 2022 survey by the National Community Pharmacists Association, 87% of pharmacists say TE codes make their job easier. They check the Orange Book at least once a week. That’s not just routine-it’s critical. A single mistake could mean a patient gets a drug that doesn’t work as well.
And it saves money. Generic drugs make up 90% of all prescriptions filled in the U.S., but only cost 23% of what brand-name drugs do. In 2023, that added up to $370 billion in savings. The TE code system is what makes that possible. Without it, pharmacies couldn’t confidently swap drugs. Doctors wouldn’t trust substitutions. Patients would pay more.
The Hidden Problems
For simple pills-like tablets you swallow-the system works incredibly well. Bioequivalence studies are straightforward: measure how much of the drug enters the bloodstream and how fast. If it matches the brand within a narrow range, it gets an A.
But not all drugs are that simple.
Take inhalers. A generic asthma inhaler might have the same active ingredient and dose, but if the propellant or nozzle design is slightly different, the way the medicine reaches the lungs could change. That’s why many get a BN code-even if they’re clinically effective. The same goes for topical creams, injectables, and suppositories. The current testing methods just don’t capture how the drug behaves in the body.
Dr. Duxin Sun from the University of Michigan pointed out in 2022 that these codes can mislead. A BT-rated cream might be just as good as the brand, but because the FDA can’t prove bioequivalence with current tools, it’s stuck with a B. That leads to confusion. A 2022 American Medical Association survey found that 42% of physicians didn’t understand what a B code meant. Some thought it meant “unsafe.” Others refused to allow substitution even when the patient had used the generic without issues.
And then there’s the problem of multiple reference drugs. If a generic matches Brand A, but the doctor prescribed Brand B, and Brand A and Brand B aren’t equivalent to each other, the pharmacist can’t substitute-even if the generic is AB-rated. That’s why you see AB1, AB2, etc. It’s complicated, and it’s not always clear to patients or even some providers.
What’s Changing?
The FDA knows the system isn’t perfect. In 2022, they released a draft guidance to update how they evaluate complex drugs. They’re working on better ways to test inhalers, creams, and injectables-using methods beyond just blood levels. They’re also expanding their Product-Specific Guidances (PSGs) to 1,850 documents as of August 2023. These are detailed roadmaps for manufacturers to prove bioequivalence for specific drugs.
The goal? Reduce the number of B-rated products for complex generics by 30% by 2027. That’s ambitious. But it’s necessary. As more complex drugs go generic-like biologics and long-acting injectables-the old system just won’t cut it.
Right now, about 90% of the 14,000 products listed in the Orange Book have an A rating. That’s impressive. But the remaining 10%? Those are the hardest cases. And they’re growing. Between 2018 and 2022, B-rated applications for complex generics rose 22%.
What Should You Do?
If you’re a patient: don’t panic if your generic has a B code. Talk to your pharmacist or doctor. Ask if it’s safe for you. Many B-rated drugs are perfectly fine-they just haven’t been officially cleared for automatic substitution.
If you’re a pharmacist: always check the Orange Book before substituting. Don’t assume a generic is interchangeable just because it’s cheaper. Use the code. If it’s B, follow your state’s rules. Some require notification. Some require consent. Know your laws.
If you’re a prescriber: understand what the codes mean. If a patient’s prescription says “generic,” but the code is B, don’t automatically assume it’s a problem. Ask for clarification. The FDA’s system is meant to guide-not dictate-clinical decisions.
The bottom line? Therapeutic equivalence codes are the backbone of affordable medicine in the U.S. They’re not perfect, but they’re the best system we have. And they’re getting better.
What does an AB code mean on a generic drug?
An AB code means the generic drug has been proven to be therapeutically equivalent to the brand-name version. It has the same active ingredient, strength, dosage form, and route of administration, and has passed bioequivalence testing-meaning it delivers the same amount of medicine into your bloodstream at the same rate as the brand. Pharmacists can legally substitute AB-rated drugs without needing permission from the prescriber in most states.
Can a drug with a B code still be used instead of the brand?
Yes, but it requires more caution. A B code doesn’t mean the drug is unsafe or ineffective. It means the FDA hasn’t confirmed that it’s interchangeable with the brand under all conditions. For example, a B-rated topical cream might work just as well for many patients. But because bioequivalence testing is harder for creams, the FDA can’t guarantee it for everyone. Your doctor may still prescribe it, and your pharmacist may fill it-but they should check with you and your prescriber first.
Why do some generic drugs have different AB numbers like AB1 and AB2?
When there’s more than one brand-name drug approved as a reference for the same generic, the FDA assigns different AB numbers to match them. For example, if Generic X is bioequivalent to Brand A (AB1) and Brand B (AB2), but Brand A and Brand B are not equivalent to each other, then Generic X can only be substituted for the brand it matches. This prevents accidental substitutions that could lead to differences in how the drug works.
Are over-the-counter (OTC) drugs given therapeutic equivalence codes?
No. The FDA’s therapeutic equivalence system only applies to prescription drugs. OTC medications, like pain relievers or antacids, are not assigned TE codes. This is because they’re not subject to the same substitution rules as prescription drugs. Pharmacists can still substitute OTC products based on label claims, but they don’t rely on the Orange Book for guidance.
How often is the Orange Book updated?
The Orange Book is updated monthly. New drug approvals, code changes, and withdrawals are published each month. Pharmacists and prescribers are encouraged to check the online version regularly, as a drug’s TE code can change if new data emerges-for example, if a previously B-rated product later proves bioequivalent and gets upgraded to an A rating.
Nishan Basnet
March 21, 2026 AT 20:38The Orange Book is one of those unsung heroes of American healthcare. I work as a pharmacist in Delhi, and I check it daily. AB-rated generics? I swap them without a second thought. But I’ve had patients come in with B-rated creams and panic, thinking they got a ‘fake’ drug. I spend 10 minutes explaining that ‘B’ doesn’t mean ‘bad’-it means ‘we need more data.’ It’s frustrating, but necessary. This system saves lives and money. We just need better public education.
Allison Priole
March 23, 2026 AT 14:46omg i had no idea about all this 😳 like i just assumed generic = same thing, right? but now i’m like… wait so my asthma inhaler that’s way cheaper has a BN code?? does that mean it’s kinda sketchy?? or just… not officially approved to swap?? i’m so confused but also kind of obsessed now??
Bryan Woody
March 23, 2026 AT 19:44Of course the FDA can’t test inhalers properly. They’re still using 1980s tech to evaluate 2020s medicine. Bioequivalence? Ha. You can’t measure lung deposition with blood levels. It’s like trying to judge a chef by tasting the spoon. And yet somehow we’re surprised when patients get worse on generics? What a shock. The system is a joke. And the AB1/AB2 nonsense? That’s not science. That’s spreadsheet warfare.
Chris Dwyer
March 24, 2026 AT 20:04Big picture: this system works because we trust it. Pharmacists aren’t just cashiers-they’re clinical gatekeepers. I’ve seen B-rated topical creams work better than the brand. I’ve had patients tell me their eczema cleared up after switching. But we can’t say that out loud because the code says ‘B.’ We need to update the science, not punish patients for outdated methods. The FDA’s draft guidance? Good start. Let’s fund the research. Let’s build better tools. This isn’t about saving money anymore-it’s about saving lives.
Timothy Olcott
March 25, 2026 AT 16:40THIS IS WHY AMERICA IS FALLING APART 😡 The FDA lets foreign labs test our drugs and then slaps an AB code on it? No wonder people get sick. I’ve seen reports-70% of generics are made in China and India. They’re cutting corners. They’re not testing bioequivalence. They’re just copying the pill shape and calling it a day. And now we’re told to trust a letter? I’d rather pay double and know my drug was made in the USA. #BuyAmerican #FDAcorrupt
Desiree LaPointe
March 25, 2026 AT 21:35How quaint. A system built on 1980s assumptions, still running on a spreadsheet, and we call it ‘the backbone of affordable medicine.’ Please. The real backbone is the pharmaceutical industry’s profit margins. The Orange Book is a bureaucratic theater. AB1, AB2? That’s not a scientific classification-that’s a legal loophole for manufacturers to game the system. And don’t get me started on how ‘bioequivalence’ is measured using healthy young men in clinical trials. Real patients? Diabetics? Elderly? Pregnant? We don’t care. We just want the code to say ‘A.’
Jackie Tucker
March 26, 2026 AT 08:42It’s ironic, really. We’ve reduced medicine to a binary: A or B. As if human biology is a software update. But we’re not machines. We’re not even molecules. We’re complex, adaptive, messy systems. And yet we demand a single letter to determine whether a person lives or dies. The real tragedy isn’t the B-rated drugs-it’s that we’ve outsourced clinical judgment to a government database. We’ve turned healing into a compliance form. And we call it progress.
Thomas Jensen
March 26, 2026 AT 20:50Wait… so the FDA doesn’t test inhalers properly? And they still let them be sold? What if the propellant is laced with something? What if the nozzle is designed to deliver a microchip? I read somewhere that the CDC has been tracking abnormal lung patterns since 2019. Coincidence? I don’t think so. And what about the AB1/AB2 codes? That’s not science. That’s a backdoor for Big Pharma to lock out generics. They want you to keep buying the brand. They’re afraid of competition. This isn’t about safety. It’s about control. They’re lying to us.
matthew runcie
March 28, 2026 AT 09:25Just wanted to say thanks for writing this. I’m a med student and I’ve been confused about TE codes for months. The Orange Book feels like a secret society handbook. This broke it down in a way that actually stuck. Also-yes, the B-rated cream I’ve been using for my psoriasis works fine. My dermatologist didn’t even know the code. We just called it ‘the good one.’ Maybe the system needs to evolve, but the people using it? They’re doing their best.